Cat's Claw (Uncaria tomentosa) for Immunity and Arthritis: Big Claims, Thin Trial Record

Cat's claw (Uncaria tomentosa) is a vine native to the Amazon, named for the curved thorns where leaves meet stem. It is sold in capsules and teas for arthritis, immunity, "auto-immune balance," cancer support, and gastrointestinal complaints. The label claims sweep across most chronic disease categories. The clinical trial literature is much narrower than the marketing suggests, and the few positive trials are small and concentrated in a single research group.

The Mur rheumatoid arthritis trial

The most-cited clinical study is Mur and colleagues 2002, a 24-week double-blind RCT in 40 patients with active rheumatoid arthritis on sulfasalazine or hydroxychloroquine. Patients received a freeze-dried pentacyclic oxindole alkaloid (POA) chemotype of U. tomentosa or placebo. The treatment arm showed a 53 percent reduction in tender joint count versus 24 percent on placebo by week 24 [1]. The trial was rigorous but small, and the chemotype distinction matters because tetracyclic oxindole alkaloids (TOAs) appear to antagonize the POA effect — most retail products do not specify which chemotype they contain.

Osteoarthritis: one trial, modest effect

Piscoya and colleagues 2001 reported that 100 mg/day of a freeze-dried cat's claw preparation reduced pain in osteoarthritis of the knee over four weeks compared with placebo [2]. The effect was modest and the trial small. Replication has not been forthcoming, and the trial preceded modern OA trial standards.

Immune cell findings versus clinical immunity

Cell culture and animal work has shown that cat's claw extracts increase white blood cell phagocytic activity, modulate NF-kB, and inhibit TNF-alpha production. A small healthy-volunteer trial reported increased lymphocyte counts after eight weeks of supplementation [3]. The leap from these cellular and biomarker findings to "immune support" or "boosting immunity" against infections is unsupported. No RCT has shown that cat's claw reduces incidence or severity of upper respiratory infections, the most common clinical immunity outcome studied for other herbs.

The cancer claim

U. tomentosa extracts induce apoptosis in various cancer cell lines and slow tumor growth in some animal models. Two small human reports describe immunological changes in breast cancer patients taking cat's claw alongside chemotherapy, with subjective fatigue reduction but no survival or progression data [4]. There is no credible evidence that cat's claw treats or prevents any human cancer. Patients should not substitute it for evidence-based oncologic care.

Safety and interactions

Cat's claw has been reported to cause acute interstitial nephritis in case reports, and a 2001 case of acute renal failure in a patient with systemic lupus erythematosus was attributed to U. tomentosa use [5]. The herb inhibits CYP3A4, raising concerns for interactions with HIV protease inhibitors, certain immunosuppressants, and oral contraceptives. Animal studies suggest possible immunomodulatory effects that could interfere with rejection prophylaxis in transplant recipients. The historical Amazonian use as a contraceptive raises pregnancy concerns; pregnant individuals should avoid it.

The honest summary

Cat's claw has one credibly positive small RCT in RA and a single small OA trial. The rest of the marketing rests on in vitro work and reputation. Among supplements people consider for inflammatory arthritis, curcumin, boswellia, and omega-3s have substantially stronger evidence bases. For "immunity," there is no clinical reason to choose cat's claw over better-studied options. The product is not benign — rare nephrotoxicity and meaningful CYP3A4 interactions mean physician oversight is warranted, not optional.